Replies

Something for folks to consider as another option, if, they ever find themselves with more than a mild bout of covid.

Zyesami (aka Aviptadil / RLF-100).

The FDA's decision on an Emergency Use Authorization should be coming in the next few days/weeks. It's already being used elsewhere on emergency use.

This is a patented formulation of Vasoactive Intestinal Polypeptide (VIP is naturally found in the body) and was initially being tested as a treatment for very serious covid cases, but other formulations are being tested on more mild cases. [2][3][4]

This therapeutic has a multimodal mechanism of action: decrease of inflammatory cytokines release leading to prevention of cytokine storm syndrome and viral replication, immunomodulating effect, vasodilating and bronchodilating effects, and prevention of surfactant depletion (surfactant coats the inside of the lungs, which can be lost during COVID-19 and lead to respiratory failure).

Information for those with critical covid in respiratory failure:

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) (SAMICARE)
Patients with Critical COVID-19 and respiratory failure who are ineligible for enrollment in NCT04311697, who live more than 50 miles from an existing collaborating research center, or who are already hospitalized and cannot safely be transferred to a collaborating research facility may be considered for expanded access by the sponsor.
Treating physicians must complete FDA Form 3396 and receive a letter of authorization from NeuroRx, along with local IRB authorization.
Please refer to FDA guidance for Individual Patient Expanded Access https://www.fda.gov/media/91160/download

More information: https://clinicaltrials.gov/ct2/show/NCT04453839

Now, if only Dr. Fraudchi et. al would get past their obsession with vaccines, and vaccines only...there are a number of great therapeutic candidates out there that could be of immense benefit to lowering the death rate from covid.

The current Zyesami/Aviptadil trial information in the U.S.:

Row	Status	Study Title	Conditions	Interventions	Locations
1	Recruiting	A Clinical Study Evaluating Inhaled Aviptadil on COVID-19	Covid19	Drug: Inhaled Aviptadil Drug: Placebo	Başkent University School of Medicine Ankara, Turkey Hacettepe University School of Medicine Ankara, Turkey Health Sciences University Yedikule Training and Research Hospital Istanbul, Turkey
2	Recruiting	Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS	Covid19 Corona Virus Infection ARDS Aviptadil	Drug: Aviptadil 67μg Drug: Placebo 0.9% NaCl solution	Cantonal Hospital Baselland Liestal Liestal, BL, Switzerland Cantonal Hospital St.Gallen St.Gallen, Switzerland
3	Completed	Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure	Critical COVID-19 With Respiratory Failure Acute Respiratory Distress Syndrome (ARDS) Corona Virus Infection Acute Lung Injury	Drug: Aviptadil by intravenous infusion + standard of care Drug: Normal Saline Infusion + standard of care	St. Jude Medical Center Fullerton, California, United States University of California - Irvine Irvine, California, United States Miller School of Medicine / University of Miami Medical Center Miami, Florida, United States (and 7 more...)
4	Recruiting	Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19	SARS-CoV 2 COVID ARDS (and 3 more...)	Drug: ZYESAMI™ (aviptadil acetate) Drug: Placebo Device: Nebulized administration of ZYESAMI™ or Placebo	St. Jude Medical Center Fullerton, California, United States University of California - Irvine Irvine, California, United States University of Miami Leonard M. Miller School of Medicine (UMMSM) Miami, Florida, United States (and 4 more...)
5	Available	ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)	Critical COVID-19 With Respiratory Failure	Drug: ZYESAMI (aviptadil acetate)	Dignity Health-Mercy Gilbert Medical Center Gilbert, Arizona, United States Honor Health Shea Medical Center Scottsdale, Arizona, United States Kaiser Permanente Baldwin Park, California, United States (and 22 more...)
6	Recruiting	ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19	Covid19	Biological: Remdesivir Drug: Remdesivir Placebo Biological: Aviptadil (and 2 more...)	Banner University Medical Center Tucson (Site 206-004), 1501 N. Campbell Avenue Tucson, Arizona, United States Community Regional Medical Center (UCSF Fresno) (Site 203-005), 2823 Fresno Street Fresno, California, United States VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street Loma Linda, California, United States (and 29 more...)
7	Recruiting	I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients	COVID-19	Drug: Remdesivir Drug: Pulmozyme Drug: IC14 (and 4 more...)	University of Alabama at Birmingham Birmingham, Alabama, United States UC Davis Medical Center Davis, California, United States Long Beach Memorial Medical Center Long Beach, California, United States (and 16 more...)

https://www.clinicaltrials.gov/ct2/results?term=Aviptadil&cond=Covid19&draw=1&rank=7#rowId6